24/7 Wall St. on MSN3 天
Goldman Sachs Sees 2025 Dividend Growth and 4 High-Yield Passive Income Stocks Are Strong Buys
Four Goldman Sachs stock picks make sense for growth and income investors charting a course for the rest of what could be a ...
pharmaphorum2 天
FDA ‘breakthrough’ status – a new tool for building oncology brands?
This explains why Nexavar, Sutent, Afinitor, and Votrient all launched first in renal cell carcinoma, a tumor with an incidence of less than 60,000 in the United States, before pursuing ...
pharmaphorum2 天
Blueprint pays the price of Ayvakit phase 3 miss as FDA rejects drug
Pfizer’s Sutent (sunitinib), Stivarga and Ayvakit – said the FDA’s head of oncologic diseases Richard Pazdur. “Today’s approval provides a new treatment option for patients who have ...
Cure Today3 天
SBRT May Offer Best Control Rates for Larger RCC Tumors, Study Finds
Among patients with renal cell carcinoma, those with larger tumors may yield the most benefit from SBRT compared with other ablative options. Among patients with renal cell carcinoma (RCC), a type of ...
Medscape6 天
Reversible Posterior Leukoencephalopathy Syndrome: Report of Three Cases
Reversible posterior leukoencephalopathy syndrome is characterized clinically by headache, abnormalities of mental status and visual perception, and seizures. Despite its diverse causes, common ...